SCHEMBL31568

SCHEMBL31568

Cc1nc2ccc(C(=O)N3CCCCC3)cn2c1-c1cccc(C(=O)NC(C)C)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ F2RL1 P55085 1/20 0.56
▸ AKT1 P31749 1/20 0.45
▸ AKT2 P31751 1/20 0.45
▸ POLB P06746 1/20 0.41
▸ HPGD P15428 5/20 0.41
▸ MEN1 O00255 5/20 0.41
▸ KMT2A Q03164 5/20 0.41
▸ GAA P10253 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ PRKD1 Q15139 2/20 0.41
▸ ALDH1A1 P00352 3/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ HSP90AA1 P07900 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ ADORA2A P29274 1/20 0.40
▸ ADORA1 P30542 1/20 0.40
▸ TRPV3 Q8NET8 1/20 0.40
▸ GGPS1 O95749 1/20 0.40
▸ NPC1 O15118 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15071134 0.86 F2RL1 (0.57) F2RL1POLBHPGDMEN1KMT2A
SCHEMBL15071137 0.85 F2RL1 (0.59) F2RL1HPGDMEN1KMT2AGAA
SCHEMBL31560 0.85 F2RL1 (0.63) F2RL1HPGDMEN1KMT2AALDH1A1
SCHEMBL15071136 0.84 F2RL1 (0.62) F2RL1HPGDMEN1KMT2AALDH1A1
SCHEMBL15071141 0.84 F2RL1 (0.61) F2RL1HPGDMEN1KMT2AALDH1A1
SCHEMBL15071131 0.83 F2RL1 (0.61) F2RL1HPGDMEN1KMT2AALDH1A1
SCHEMBL15071100 0.83 F2RL1 (0.77) F2RL1AKT1AKT2HPGDMEN1
SCHEMBL15071144 0.82 F2RL1 (0.60) F2RL1HPGDMEN1KMT2AHTT
SCHEMBL31506 0.82 F2RL1 (0.57) F2RL1HPGDMEN1KMT2AGAA
SCHEMBL15071143 0.81 F2RL1 (0.74) F2RL1AKT1AKT2POLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130165652-A1 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME NEOPHARM CO.,LTD. (KR) 2013-06-27 — — US disclosed
WO-2012026765-A2 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME (주)네오팜 (KR) 2012-03-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165652-A1 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME F2RL1, F2R, FPR2 F2RL1 1/4885AKT1 669/4885AKT2 475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback